Growth Capitalist (https://growthcapitalist.com/tag/biotech/page/68/)
Alliqua Inc. (ALQA) announced that it has raised $14,975,009 in a Common Stock transaction. The common stock was sold at $7.00 per share, an approximate 3% premium to the market price ($6.79) of ALQA at deal announcement. A series of 427,857 60-Month Warrants with an exercise price of $10.50 per share (54.64% premium) was issued to the investors in this transaction. Issuer counsel was Haynes and Boone, LLP. The transaction closed on April 15, 2014.
CEL-SCI Corporation (CVM) announced that it has raised $9,979,521 in a CMPO/Overnight transaction. The common stock was sold at $1.40 per share, an approximate 7% discount to the market price ($1.51) of CVM at deal announcement. A series of 1,782,057 6-Month Warrants with an exercise price of $1.58 per share (4.64% premium) was issued to the investors in this transaction. Dawson James Securities, Inc. and Laidlaw & Company (UK) Ltd. acted as Joint Book-Running Managers on the transaction.
BioPharmX Corporation (BPMX) announced that it has raised $1,500,000 in a Convertible Preferred Stock transaction. The fixed conversion price of the Convertible Preferred Stock is $1.85 per share. A series of 405,406 0-Month Warrants with an exercise price of $3.70 per share was issued to the investors in this transaction. The transaction closed on 04/11/2014. via PlacementTracker.
Northwest Biotherapeutics, Inc. (NWBO) announced that it has raised $14,999,998 in a Registered Direct transaction. The common stock was sold at $6.60 per share, an approximate 8% discount to the market price ($7.17) of NWBO at deal announcement. H.C. Wainwright & Co. acted as the exclusive agent on the transaction. The transaction is expected to close on April 14, 2014.
